Enterprise Value

62.9M

Cash

22.92M

Avg Qtr Burn

-15.17M

Short % of Float

1.31%

Insider Ownership

12.07%

Institutional Own.

66.19%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

AT-001 Details
Genetic disorder, Hemophilia, Diabetic cardiomyopathy

Big Mover™

Susp. Mover™

Phase 3

Data readout

Govorestat (AT-007) Details
Sorbitol dehydrogenase deficiency

Phase 3

Data readout

Govorestat (AT-007) Details
Congenital disorder of glycosylation, Phosphomannomutase 2 deficiency

Phase 2

Update

AT-003 Details
Diabetic retinopathy

Phase 1

Update

AT-104 Details
Leukemia, B-cell acute lymphoblastic leukemia, T-cell lymphoma

Failed

Discontinued